Healios K.K. (HLOSF)
USD 1.35
(0.0%)
USD 1.35
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -2.19 Billion JPY | -284306.72% |
| 2022 | -770.02 Thousand JPY | 97.2% |
| 2021 | -27.53 Million JPY | -12.81% |
| 2020 | -24.4 Million JPY | 67.08% |
| 2019 | -74.13 Million JPY | 99.09% |
| 2018 | -8.12 Billion JPY | 48.94% |
| 2017 | -15.91 Billion JPY | -198.86% |
| 2016 | -5.32 Billion JPY | -6868.19% |
| 2015 | -76.44 Million JPY | 96.07% |
| 2014 | -1.94 Billion JPY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -2.79 Billion JPY | 20.87% |
| 2024 Q1 | -23.33 Million JPY | -61.28% |
| 2023 Q1 | -150.54 Thousand USD | 80.45% |
| 2023 FY | -2.19 Billion JPY | -284306.72% |
| 2023 Q3 | -16.65 Million USD | -1392.59% |
| 2023 Q4 | -15.52 Million USD | 6.82% |
| 2023 Q2 | 1.28 Million USD | 955.99% |
| 2022 Q3 | 1.49 Million JPY | 7.19% |
| 2022 FY | -770.02 Thousand JPY | 97.2% |
| 2022 Q4 | -770.02 Thousand JPY | -151.61% |
| 2022 Q1 | -1.2 Billion JPY | 62.05% |
| 2022 Q2 | 1.39 Million JPY | 100.12% |
| 2021 Q1 | -7.11 Million JPY | 99.72% |
| 2021 FY | -27.53 Million JPY | -12.81% |
| 2021 Q4 | -3.17 Billion JPY | 37.93% |
| 2021 Q3 | -5.1 Billion JPY | -160673.9% |
| 2021 Q2 | 3.18 Million JPY | 144.71% |
| 2020 FY | -24.4 Million JPY | 67.08% |
| 2020 Q1 | -6.73 Billion JPY | 16.43% |
| 2020 Q2 | -4.67 Billion JPY | 30.55% |
| 2020 Q3 | -3.82 Billion JPY | 18.2% |
| 2020 Q4 | -2.52 Billion JPY | 34.12% |
| 2019 Q1 | -7.58 Billion JPY | 14.45% |
| 2019 Q4 | -8.05 Billion JPY | -7.99% |
| 2019 Q3 | -7.46 Billion JPY | -22.41% |
| 2019 Q2 | -6.09 Billion JPY | 19.6% |
| 2019 FY | -74.13 Million JPY | 99.09% |
| 2018 FY | -8.12 Billion JPY | 48.94% |
| 2018 Q4 | -8.86 Billion JPY | 17.69% |
| 2018 Q2 | -12 Billion JPY | 1.51% |
| 2018 Q3 | -10.76 Billion JPY | 10.31% |
| 2018 Q1 | -12.18 Billion JPY | 26.89% |
| 2017 Q3 | -13.92 Billion JPY | -2.34% |
| 2017 FY | -15.91 Billion JPY | -198.86% |
| 2017 Q1 | -6.74 Billion JPY | -26.54% |
| 2017 Q2 | -13.6 Billion JPY | -101.89% |
| 2017 Q4 | -16.66 Billion JPY | -19.69% |
| 2016 FY | -5.32 Billion JPY | -6868.19% |
| 2016 Q4 | -5.32 Billion JPY | 10.82% |
| 2016 Q3 | -5.97 Billion JPY | 9.8% |
| 2016 Q2 | -6.62 Billion JPY | -13.24% |
| 2016 Q1 | -5.84 Billion JPY | 36.41% |
| 2015 FY | -76.44 Million JPY | 96.07% |
| 2015 Q3 | -9.54 Billion JPY | -8.69% |
| 2015 Q2 | -8.78 Billion JPY | 0.0% |
| 2015 Q4 | -9.19 Billion JPY | 3.67% |
| 2014 FY | -1.94 Billion JPY | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 13993.294% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 53280.846% |
| SQZ Biotechnologies Company | -36.23 Million USD | -5943.38% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 5217.659% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | -34636.96% |
| Mesoblast Limited | 55.85 Million USD | 4020.638% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 236298.562% |
| Genus plc | 190.6 Million USD | 1249.003% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 98050.114% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 180512.031% |
| Marizyme, Inc. | 18.56 Million USD | 11893.832% |
| ContraFect Corporation | -6.02 Million USD | -36242.516% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 322158.824% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | 1626671.796% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 189639.989% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 97770.492% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 39904.46% |
| MultiCell Technologies, Inc. | 90.04 USD | 2432252432.297% |
| Accustem Sciences Inc. | -733.97 Thousand USD | -298274.066% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 17016.422% |
| EV Biologics, Inc. | 1.36 Million USD | 160191.113% |
| Q BioMed Inc. | 4.06 Million USD | 54040.78% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 7267.638% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 351984.106% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 217423.135% |
| Biomind Labs Inc. | 711.4 Thousand USD | 307942.823% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 109.8 Million USD | 2094.463% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 17200.571% |
| Skye Bioscience, Inc. | -5.72 Million USD | -38177.418% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 254679.821% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | 1566578.785% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 38872.248% |
| IMV Inc. | 7.67 Million USD | 28650.864% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | 11023404.978% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 99555.899% |
| GB Sciences, Inc. | 1.74 Million USD | 125435.085% |
| Alpha Cognition Inc. | -183.78 Thousand USD | -1191490.311% |
| HST Global, Inc. | 96.79 Thousand USD | 2262660.309% |
| CSL Limited | 10.52 Billion USD | 120.806% |
| Halberd Corporation | 144.72 Thousand USD | 1513356.542% |
| Enzolytics Inc. | 981.65 Thousand USD | 223192.407% |
| Resverlogix Corp. | 6.45 Million USD | 34048.225% |
| Affymax, Inc. | -5.59 Million USD | -39028.104% |
| SYBLEU INC | 473.71 Thousand USD | 462404.26% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | -325265.591% |
| argenx SE | -2.02 Billion USD | -7.943% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 5142.133% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | -4558.385% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 80953.13% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | -24674.002% |
| AVAX Technologies, Inc. | -5.9 Million USD | -36998.479% |
| Zenith Capital Corp. | 10.06 Thousand USD | 21760831.32% |
| Genscript Biotech Corporation | -1.06 Billion USD | -106.344% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | 1092739.898% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 91884.107% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | 1331334.157% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 3717.099% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 109633.298% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -2.57 Million USD | -85112.947% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 608923.775% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 10900.947% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | -11955353.652% |
| BioStem Technologies, Inc. | 4.47 Million USD | 49071.257% |
| ONE Bio Corp. | 9.04 Million USD | 24325.57% |
| Reve Technologies, Inc. | 201.25 Thousand USD | 1088277.129% |
| Burzynski Research Institute, Inc. | -1310.00 USD | -167175472.519% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | 1062088.1% |
| Agentix Corp. | 37.63 Thousand USD | 5819769.953% |
| LadRx Corporation | -2.03 Million USD | -107439.079% |
| Cell Source, Inc. | 9.23 Million USD | 23821.912% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | -10730985.849% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 344891.212% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 344891.212% |
| NovAccess Global Inc. | 2.17 Million USD | 100629.501% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 31071.697% |
| Itoco Inc. | 228.3 Thousand USD | 959343.118% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | 1610524.373% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 44279.948% |
| Kadimastem Ltd | -253.1 Thousand USD | -865163.807% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 545080.826% |
| CytoDyn Inc. | 20.26 Million USD | 10908.41% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | -338485216.847% |
| Mobile Lads Corp. | 484.23 Thousand USD | 452362.552% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | -23628726.737% |
| Qrons Inc. | 351.42 Thousand USD | 623273.518% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 28519.406% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | -877233.547% |
| Rebus Holdings, Inc. | 305 Thousand USD | 718132.787% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 49235.948% |
| International Stem Cell Corporation | 2.59 Million USD | 84655.985% |
| Bioxytran, Inc. | 1.89 Million USD | 115429.078% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | 3508984.367% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 100517.259% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 63874.024% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 25705.051% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 283555.884% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | -175100.0% |
| Neutra Corp. | 52.18 Thousand USD | 4196547.391% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | -87887.143% |
| PureTech Health plc | -167.19 Million USD | -1209.832% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | -894113.337% |
| IXICO plc | -4.44 Million USD | -49173.42% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 16667.063% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 4092.635% |
| CSL Limited | 10.52 Billion USD | 120.806% |
| Cellectis S.A. | -43.81 Million USD | -4897.846% |